Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;18(10):974-81.
doi: 10.1038/gim.2015.212. Epub 2016 Feb 4.

Improving performance of multigene panels for genomic analysis of cancer predisposition

Brian H Shirts  1 , Silvia Casadei  2 , Angela L Jacobson  1 , Ming K Lee  2 , Suleyman Gulsuner  2 , Robin L Bennett  2 , Margaret Miller  3 , Sarah A Hall  4 , Heather Hampel  5 , Fuki M Hisama  2 , Lorraine V Naylor  2 , Cathleen Goetsch  6 , Kathleen Leppig  2   7 , Jonathan F Tait  1 , Sheena M Scroggins  1 , Emily H Turner  1 , Robert Livingston  1 , Stephen J Salipante  1 , Mary-Claire King  2   8 , Tom Walsh  2 , Colin C Pritchard  1
Affiliations
Free article

Improving performance of multigene panels for genomic analysis of cancer predisposition

Brian H Shirts et al. Genet Med. 2016 Oct.
Free article

Abstract

Purpose: Screening multiple genes for inherited cancer predisposition expands opportunities for cancer prevention; however, reports of variants of uncertain significance (VUS) may limit clinical usefulness. We used an expert-driven approach, exploiting all available information, to evaluate multigene panels for inherited cancer predisposition in a clinical series that included multiple cancer types and complex family histories.

Methods: For 1,462 sequential patients referred for testing by BROCA or ColoSeq multigene panels, genomic DNA was sequenced and variants were interpreted by multiple experts using International Agency for Research on Cancer guidelines and incorporating evolutionary conservation, known and predicted variant consequences, and personal and family cancer history. Diagnostic yield was evaluated for various presenting conditions and family-history profiles.

Results: Of 1,462 patients, 12% carried damaging mutations in established cancer genes. Diagnostic yield varied by clinical presentation. Actionable results were identified for 13% of breast and colorectal cancer patients and for 4% of cancer-free subjects, based on their family histories of cancer. Incidental findings explaining cancer in neither the patient nor the family were present in 1.7% of subjects. Less than 1% of patients carried VUS in BRCA1 or BRCA2. For all genes combined, initial reports contained VUS for 10.5% of patients, which declined to 7.5% of patients after reclassification based on additional information.

Conclusions: Individualized interpretation of gene panels is a complex medical activity. Interpretation by multiple experts in the context of personal and family histories maximizes actionable results and minimizes reports of VUS.Genet Med 18 10, 974-981.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. PLoS Genet. 2013;9(8):e1003709 - PubMed
    1. J Clin Oncol. 2015 Jun 20;33(18):2084-91 - PubMed
    1. Am J Hum Genet. 2012 Dec 7;91(6):1022-32 - PubMed
    1. Am J Hum Genet. 2014 Oct 2;95(4):421-36 - PubMed
    1. Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5 - PubMed

Publication types

-